|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.92 USD | +0.22% |
|
+0.79% | +24.46% |
| Apr. 12 | Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48 | MT |
| Apr. 08 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
FRANKFURT, Feb 7 (Reuters) - The European Union's drugs regulator said on Wednesday it will assess the impact on the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk. (Reporting by Ludwig Burger)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 886.6 DKK | +2.28% | +2.36% | 566B | ||
| 733.5 USD | +1.19% | +0.99% | 661B | ||
| 55.92 USD | +0.22% | +0.79% | 10.12B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +24.46% | 10.12B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
CATALENT, INC. 
